Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Conditions

• EGFR Mutated Non-small Cell Lung Cancer Patients
• EGFR Mutation Positive Non-small Cell Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• NXP900 — DRUG
  NXP900 is an orally administered inhibitor of SRC family kinases (SFK)
• Osimertinib — DRUG
  Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor

Study Details

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Key Dates

Start date

Dec 18, 2025

Status verified

Dec 2025

Primary completion

Dec 31, 2026

Completion

Jun 30, 2027

Study Design

Enrollment

18 participants (estimated)

Allocation

NA

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Dose Exploration (Part 1)
  Escalating doses of NXP900 given with osimertinib

Primary Outcome Measure

Number of patients with treatment related adverse events and/or clinical laboratory abnormalities [ Time Frame: Up to 30 days post treatment ]

Central Contacts

• Erin Belshaw
  12016278129
  [email protected]
• Shay Shemesh
  [email protected]

Locations (3)

Find similar trials in Boston, MA